- A method for preparing DL-lysine
-
The invention provides a method for preparing DL-lysine with chiral lysine salt as a raw material. The method specifically comprises the following steps: dissolving chiral lysine salt in an acetic acid water solution, adding salicylaldehyde or benzaldehyde as a catalyst, carrying out heating and racemization, removing solvents through vacuum distillation after racemization is completed, washing a residual solid with ethanol, obtaining DL-lysine salt, removing salt with an ion exchange column and carrying out concentration and decoloration, thus obtaining a DL-lysine solid. The preparation method has the advantages that the preparation method is lower in production cost and simple in process; pollution is not easily caused in the production process; the racemization rate of L-lysine hydrochloride can be 100%; the purity of the obtained DL-lysine finished product is more than 98%.
- -
-
Paragraph 0032; 0033
(2017/04/03)
-
- COMPOSITIONS AND METHODS FOR THE PREPARATION OF KIDNEY PROTECTIVE AGENTS COMPRISING AMIFOSTINE AND AMINO ACIDS
-
This invention relates to composition and method of preparation of AminoMedix? comprising of Amifostine, at least one amino acid (Arginine, Lysine, Histidine) with or without other pharmaceutically active compounds. The AminoMedix? composition can be applied for kidney protection during therapy using radiolabeled and non-radiolabeled compounds, contrast agents, chemotherapeutics, antibiotics and drugs showing nephrotoxic effect.
- -
-
-
- Lysine racemase from a lactic acid bacterium, Oenococcus oeni: Structural basis of substrate specificity
-
Oenococcus oeni, a lactic acid bacterium, possesses a lysine racemase, which has a specific activity towards basic amino acids. A comparison of amino acid residues around the active site suggested that Ile222 and Tyr354 of the Geobacillus stearothermophilus alanine racemase, which shares 60% sequence similarity with lysine racemase, were replaced by Thr224 and Trp355 in the O. oeni lysine racemase. T224I/W355Y double mutations significantly decreased the activity of lysine racemase, whereas I222T/Y354W double mutations endowed alanine racemase with lysine racemization activity. These results suggest that the two residues play an important role in lysine racemization.
- Kato, Shiro,Hemmi, Hisashi,Yoshimura, Tohru
-
p. 505 - 508
(2013/02/25)
-
- Powder storage container
-
PROBLEM TO BE SOLVED: To prevent a sealing member from breaking away from a device body even when the sealing member is bent. SOLUTION: A toner replenishing type developing device 4Y, 4M, 4C or 4B comprises a developing device body 4a, and a sealing member 4e. The sealing member 4e comprises an insertion and removal part 41a which a toner replenishing pipe 13Y, 13M, 13C, or 13B is inserted into and removed from, and a bending part 41b which bends by the insertion of the replenishing pipe 13Y, 13M, 13C or 13B into the insertion and removal part 41a, and is restored to its original state by the removal of the toner replenishing pipe 13Y, 13M, 13C or 13B from the insertion and removal part 41a. The bending part 41b of the sealing member 4e is formed in such a manner that the thickness t2 thereof in the insertion direction of the toner replenishing pipe 13Y, 13M, 13C or 13B at the bending part 41b is smaller than the thickness t1 of the insertion and removal part 41a in the insertion direction of the toner replenishing pipe 13Y, 13M, 13C or 13B at the insertion and removal part 41a. COPYRIGHT: (C)2007,JPOandINPIT
- -
-
-
- Kinetics and mechanism of thermal decomposition of kynurenines and biomolecular conjugates: Ramifications for the modification of mammalian eye lens proteins
-
Thermal degradation reactions of kynurenine (KN), 3-hydroxykynurenine (3OHKN), and several adducts of KN, to amino acids and reduced glutathione (GSH) have been studied at physiological temperature. These compounds are all implicated in age-related mammalian eye lens cataract formation at the molecular level. The main reaction pathway for both KN and 3OHKN is deamination viaβ-elimination to carboxyketoalkenes CKA and 3OHCKA. These reactions show a weak pH dependence below pH values of ～8, and a strong pH dependence above this value. The 3OHKN structure deaminates at a faster rate than KN. A mechanism for the deamination reaction is proposed, involving an aryl carbonyl enol/enolate ion, that is strongly supported by the structural, kinetic, and pH data. The degradation of Lys, His, Cys and GSH adducts of the CKA moieties was also studied. The Lys adduct was found to be relatively stable over 200 h at 37 °C, while significant degradation was observed for the other adducts. The results are discussed in terms of known post-translational modification reactions of the lens proteins and compared to incubation studies involving KN and related compounds in the presence of proteins.
- Kopylova, Lyudmila V.,Snytnikova, Olga A.,Chernyak, Elena I.,Morozov, Sergey V.,Forbes, Malcolm D. E.,Tsentalovich, Yuri P.
-
experimental part
p. 2958 - 2966
(2011/02/25)
-
- Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
-
The invention relates to isolated polynucleotides homologous with a portion of one strand of the human tumor suppressor gene, FEZ1, and to the tumor suppressor protein encoded thereby, Fez1. The polynucleotides are useful, for example, as probes, primers, portions of expression vectors, and the like. The invention also includes diagnostic, therapeutic, cell proliferation enhancement, and screening methods which involve these polynucleotides and protein. The invention further includes kits useful for performing the methods of the invention.
- -
-
-
- Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
-
The invention provides chemical conjugates between an immunoglobulin Fab fragment and molecular entities imparting diagnostic or therapeutic utility, whereby the only sites of conjugation on the Fab fragment are one or both of the sulfhydryl groups deriving from the selective and quantitative reduction of the inter-chain disulfide bond of said Fab fragment and whereby said molecular entities imparting diagnostic or therapeutic utility have at least one free sulfhydryl-reactive group, characterized in that the conjugation stoichiometric molar ratio molecular entity to Fab fragment is in the range from 0.95 to 1.05 or in the range from 1.95 to 2.05. The invention also provides a process for preparing said conjugates and pharmaceutical compositions thereof.
- -
-
-
- T-CELL SELECTIVE INTERLEUKIN-4 AGONISTS
-
The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T-cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T-cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R121I, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild-type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
- -
-
-
- (1 -> 3, 1 -> 4)-beta-glucanase of enhanced stability
-
A modified cereal (1→3,1→4)-β-glucanase is produced by the method of single point substitution in a native cereal (1→3,1→4)-β-glucanase enzyme, whereby the substitution: a) maintains enzyme specificity by conserving the active site groove of the native cereal (1→3,1→4)-β-glucanase enzyme; and b) effects increased thermostability over the native cereal (1→3,1→4)-β-glucanase enzyme by: i) replacing glycine by proline or alanine in helices of the cereal (1→3,1→4)-β-glucanase enzyme, in order to stiffen the enzyme amino acid chain and reduce entropy of the unfolded enzyme; ii) attaching negatively charged residues to N-termini of helices in the native cereal (1→3,1→4)-β-glucanase enzyme; iii) introducing ion pairs into the native cereal (1→3,1→4)-β-glucanase enzyme, to increase binding energy in the folded enzyme; iv) replacing lysine by arginine in the cereal (1→3,1→4)-β-glucanase enzyme, and thereby preventing lysine glycation and increasing hydrogen bonding with other parts of the enzyme; v) replacing, by glycine, an amino acid in the native cereal (1→3,1→4)-β-glucanase enzyme in which the main chain torsion angle about the N and Cα atoms is greater than 0°; or vi) creating cysteine pairs in the native cereal (1→3,1→4)-β-glucanase enzyme which can form disulphide bonds across the C and N terminals.
- -
-
-
- 3-deoxyglucosone and skin
-
The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.
- -
-
-
- Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
-
The present invention relates to primary CNS tumors and provides useful compositions and methods for reducing tumor volume and increasing the length of survival in mammals with primary CNS tumors, thereby providing a treatment for primary CNS tumors. The invention also relates to methods of identifying compounds for reducing tumor volume and increasing animal survival, which therefore relate to treating primary CNS tumors.
- -
-
-
- Compositions, methods, and kits relating to resistin-like molecules
-
The invention relates to novel nucleic acids encoding a mammalian resistin-like molecule (RELM), and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, intestinal (e.g., colonic) tumors. The invention further relates to methods of treating and detecting irritable bowel disease, inflammatory bowel disease, familial adenomatous polyposis, diabetes, insulin resistance, obesity, Syndrome X, and glucose metabolism disorders, colon cancer, breast cancer, and tongue cancer, comprising modulating or detecting RELM expression and/or production and activity of RELM polypeptide, wherein RELM encompasses resistin-like molecule α and resistin-like molecule β.
- -
-
-
- Mammalian prestin polynucleotides
-
The invention relates to mammalian prestin protein, which has been discovered to be the mammalian cochlear outer hair cell motor, and to polynucleotides encoding prestin. Full length gerbil prestin and its cDNA are described, full length murine prestin and its cDNA are described, and a partial sequence of human prestin and its chromosomal location are described.
- -
-
-
- 20(S) camptothecin glycoconjugates
-
The present invention relates to glycoconjugates of 20(S)-camptothecin, in which a 3-O-methylated β-L-fucose unit is linked to the 20-hydroxyl group of a camptothecin derivative via a thiourea-modified peptide spacer. The invention furthermore relates to processes for the preparation of the compounds according to the invention and to their use as medicaments, in particular in connection with oncoses.
- -
-
-
- Bix-azo naphthylene compounds and their use in compositions and inks for ink-jet printing
-
Compounds of the Formula (1) and salts thereof: wherein: each A independently is N, C—Cl, C—CN or C—NO2; each Ar independently is a substituted aryl group carrying a —COOH group ortho to the azo (—N═N—) group; L is an aliphatic group carrying a —COOH, —SO3H or —PO3H2group; each Z independently is —SR2, —OR3, —NR4R5or a labile atom or group; each X independently is —S—, —O— or —NR1—; each R1independently is H or optionally substituted alkyl; and R2, R3, R4and R5are independently H, optionally substituted alkyl, optionally substituted aryl or optionally substituted aralkyl; or R4and R5together with the nitrogen to which they are attached form an optionally substituted five or six membered ring, and their use in compositions and inks for ink jet printing processes and ink jet printer cartridges.
- -
-
-
- Monoclonal antibody against human telomerase catalytic subunit
-
The present invention provides a monoclonal antibody which can specifically and efficiently recognize hTERT protein; which is the catalytic subunit of telomerase, and provides a human chimeric antibody, a CDR grafted antibody, a single chain antibody, and a disulfide stabilized antibody each containing the monoclonal antibody. In addition, the present invention provides a method for detecting/quantitating hTERT protein using these antibodies, and provides diagnosis method, diagnosis agent, and therapeutic agent, for diseases, such as cancer, in which telomerase is involved using these bodies.
- -
-
-
- Thermochemical data on adducts of copper chloride with the amino acids lysine and glycine
-
Adducts of the general formula CuCl2·nlys (n = 1,2,4;lys = lysine) and CuCl2·ngly (n = 2,4;gly = glycine) were prepared by reacting the ligands with CuCl2 in solid state. The adducts were characterized by elemental analysi
- Martínez, Leandro,De Farias, Robson F.,Airoldi, Claudio
-
-
- 9-BBN: An amino acid protecting group for functionalization of amino acid side chains in organic solvents.
-
9-Borabicyclononane (9-BBN) has been utilized to protect functionalized amino acids for potential chemoselective side chain manipulation. The 9-BBN group imparts organic solubility to otherwise hydrophilic molecules and is tolerant of a wide range of reaction conditions. The high degree of solubility of these molecules in THF is particularly noteworthy. It is cleaved with either aqueous HCl or by exchange with ethylenediamine in methanol. [reaction: see text]
- Dent 3rd., William H,Erickson, W Randal,Fields, Stephen C,Parker, Marshall H,Tromiczak, Eric G
-
p. 1249 - 1251
(2007/10/03)
-
- Gene recombinant antibody and antibody fragment thereof
-
A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
- -
-
-
- Method for the preparation of 1-benzotriazolylcarbonate esters of poly(ethylene glycol)
-
The invention provides a method for preparing a 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl group of a water-soluble and non-peptidic polymer with di(1-benzotriazolyl) carbonate in the presence of an amine base and an organic solvent. The polymer backbone can be poly(ethylene glycol). The 1-benzotriazolylcarbonate ester can then be reacted directly with a biologically active agent to form a biologically active polymer conjugate or reacted with an amino acid, such as lysine, to form an amino acid derivative.
- -
-
-
- Antiviral composition derived from allium CEPA and therapeutic use thereof
-
Novel medicinal extracts derived from Allium species, preferablyAllium cepaare provided. These extracts have broad medicinal properties, especially for treatment of AIDS and other viral infections.
- -
-
-
- NON-NATURALLY OCCURRING LIPOPROTEIN PARTICLE
-
Non-naturally occurring receptor competent LDL particle comprising at least one peptide component wherein the said peptide component comprises at least a binding site for an Apo B protein receptor and at least one lipophilic substituent.
- -
-
-
- Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
-
The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin target imagin
- -
-
-
- T-cell selective interleukin-4 agonists
-
This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of interleukin 4. Further, the invention is directed to IL-4 muteins having single and double mutations represented by the designators R121E and T13D/R121E, numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
- -
-
-
- Method of using PON-1 to decrease atheroma formation
-
The invention is directed to a method of decreasing atheroma formation in a mammal comprising administering a pharmaceutically effective amount of PON-1 or its functional equivalent to a patient in need thereof. Also included herein are pharmaceutical compositions, and a method for diagnosing predisposition to hypercholesterolemia by assessing the level of native circulating PON-1.
- -
-
-
- ASSAYS FOR HOMOCYSTEINE AND HOMOCYSTEINE DESULPHURASE FROM PROTOZOAN TRICHOMONASVAGINALIS
-
The present invention relates to an assay for determining homocysteine, cysteine, O-acetyl-L-serine and/or methionine levels in a biological sample using an enzyme that catalyzes the degradation of homocysteine, cysteine, O-acetyl-L-serine and methionine. The enzyme being more particularly homocysteine desulphurase, a polynucleotide fragment encoding protozoan homocysteine desulphurase, a recombinant vector comprising a polynucleotide fragment, transformed cells, the protozoan homocysteine desulphurase polypeptide, and pharmaceutical compositions comprising recombinant homocysteine desulphurase for use in medicine or veterinary medicine.
- -
-
-
- CELL DELIVERY COMPOSITIONS
-
The present invention provides improved cell delivery compositions. In particular, the invention provides biocompatible endosomolytic agents. In a preferred embodiment, the endosomolytic agents are also biodegradable and can be broken down within cells into components that the cells can either reuse or dispose of. Preferred endosomolytic agents include cationic polymers, particularly those comprised of biomolecules, such as histidine, polyhistidine, polylysine or any combination thereof. Other exemplary endosomolytic agents include, but are not limited to, other imidazole containing compounds such as vinylimidazole and histamine. More particularly preferred are those agents having multiple proton acceptor sites and acting as a “proton sponge”, disrupting the endosome by osmolytic action. In preferred embodiments, the endosomolytic agent comprises a plurality of proton acceptor sites having pKas within the range of 4 to 7, which endosomal lysing component is polycationic at pH 4. The present invention also contemplates the use of these endosomolytic agents as delivery agents by complexation with the desired compound to be delivered. Thus, the present invention also acts as a cell delivery system comprising an endosomolytic agent, a delivery agent, and a compound to be delivered.
- -
-
-
- Composition of matter having bioactive properties
-
Particles of coordinated complex comprising a basic, hydrous polymer and a capacitance adding compound, as well as methods for their production, are described. These complexes exhibit a high degree of bioactivity making them suitable for a broad range of applications through their incorporation into conventional vehicles benefiting from antimicrobial and similar properties.
- -
-
-
- Methods of enhancing functioning of the large intestine
-
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.
- -
-
-
- TUMOR ANTIGEN PEPTIDE ORIGINATING IN SART-1
-
To provide a tumor antigen peptide derived from SART-1 and a derivative thereof, possessing functionally equivalent characteristics thereto; or a therapeutic agent, prophylactic agent or the like for a tumor, each utilizing the tumor antigen peptide.
- -
-
-
- Bacillus thuringiensis Cry1Ia-Cry1Ba hybrid toxins
-
Bacillus thuringiensishybrid toxin fragment comprising structural domains I, II and III in this order starting from the N-terminal, wherein the domains are derived from at least two different Cry proteins, domain I is domain I of any Bacillus thuringiensisCry protein or a part of said domain or a peptide substantially similar to said domain, domain II is domain II of Cry1la or a part of said domain or a peptide substantially similar to said domain, and domain III is domain III of Cry1Ba or a part of said domain or a peptide substantially similar domain.
- -
-
-
- THYMIDINE KINASE MUTANTS
-
The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution upstream from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within another aspect, one of the mutations is an amino acid substitution within a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Also provided are vectors suitable for expressing such DNA molecules, as well as methods for utilizing such vectors.
- -
-
-
- NOVEL G PROTEIN-COUPLED RECEPTOR PROTEIN AND DNA THEREOF
-
The present invention relates to a rat cerebellum-derived G-protein-coupled receptor protein, its partial peptides, and salts thereof, and a nucleic acid and its derivatives that encodes the receptor protein. The rat cerebellum-derived G-protein-coupled receptor protein of this invention and the nucleic acid and its derivatives encoding the said protein can be used for determination of ligands (agonists) for the G-protein-coupled receptor protein of this invention, prophylactic and/or therapeutic drugs for diseases related to dysfunction of the G-protein-coupled receptor protein of this invention, gene diagnostic drugs, and methods for screening compounds that change the expression level of the receptor protein of this invention and its partial peptides.
- -
-
-
- Human betacellulin-specific antibodies and uses thereof
-
Disclosed are an antibody which have a binding activity to human betacellulin protein or a mutein thereof with specificity; especially a monoclonal antibody which does not have cross reactitivity with human epidermal growth factor (EGF) and human transforming growth factor a (TGF-α), belongs to the immunoglobulin class of IgG, and,specifically binds to human betacellulin protein to neutralize biological activity thereof; a hybridoma for producing the monoclonal antibody; and a method for producing the monoclonal antibody. Said monoclonal antibody neutralizes biological activity of a human BTC protein, and bind to the protein with high sensitivity and specificity, so that they can be used as a therapeutic agent for diseases such as arterial sclerosis and cancers, and also used as a reagent for assaying the human BTC protein or a mutein thereof and as a diagnostic agent for diabetes or complications thereof.
- -
-
-
- Prolonged delivery of peptides
-
There are disclosed methods for the treatment of non-insulin dependent diabetes mellitus in a mammal comprising the prolonged administration of GLP-1 (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides.
- -
-
-
- Compositions, kits, and methods for effecting adenine nucleotide modulation of DNA mismatch recognition proteins
-
Compositions, and products comprising a MutS homolog which binds to a mismatched region of a duplex DNA molecule in the presence of ADP are provided, as are methods of binding MutS homologs to mismatched DNA in the presence of ADP. The use of MutL homolog derivatives in combination with MutS homologs is also included. Nonhuman mammals which are nullizygous for both Msh2 and p53 are also provided, as are methods of making and using the same.
- -
-
-
- Methods of enhancing functioning of the upper gastrointestinal tract
-
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the upper gastrointestinal tract including the esophagus and stomach. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of the upper gastrointestinal tract. Thus, the invention provides methods of proliferating the upper gastrointestinal tract in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the upper gastrointestinal tract, including inflammatory diseases. GLP-2 stimulates the growth of upper gastrointestinal tissue when administered in conjunction with other peptide hormones. The invention further provides pharmaceutical compositions of GLP-2 with at least one other peptide hormone, methods of enhancing the growth of upper gastrointestinal tissue and of gastrointestinal disorders by increasing serum levels of GLP-2 and at least one other peptide hormone, and kits for preforming the methods of the invention.
- -
-
-
- Method of producing a 19P2 ligand
-
The method of the present invention is suitable for the commercial high-level production of a protein or peptide which can be used as a prophylactic and therapeutic drug for various diseases such as senile dementia, cerebrovascular dementia (dementia arising from cerebrovascular disorders), dementia associated with genealogical retroplastic diseases (e.g. Alzheimer's disease, Parkinson's disease, Pick's disease, Huntington's disease, etc.), dementia associated with infectious diseases (e.g. Creutzfeldt-Jakob's and other virus diseases), dementia associated with endocrine or metabolic disease or toxicosis (e.g. hypothyroidism, vitamin B12 deficiency, alcoholism, intoxication by drugs, metals, and organic compounds), dementia associated with tumorigenic diseases (e.g. brain tumor), dementia associated with traumatic diseases (e.g. chronic subarachnoidal hemorrhage), and other types of dementia, depression, hyperactive child syndrome (microencephalopathy), and disturbance of consciousness. Additionally, the ligand polypeptide of the present invention has prolactin secretion-stimulating and inhibiting activities.
- -
-
-
- Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder
-
The invention includes a substantially pure preparation of a peptide having corticotropin release inhibiting factor (CRIF) activity comprising at least three contiguous amino acids contained within the amino acid sequence positioned between the fourth and fifth thyrotropin releasing hormone (TRH) sequence on a prepro-TRH protein. The CRIF peptide further comprises the fourth uncleaved TRH portion of prepro-TRH positioned at the amino terminus of CRIF. Compositions, methods of diagnosis and methods of treating CRIF related diseases are also included in the invention.
- -
-
-
- Rat glutathione synthetase gene
-
The present invention relates to recombinant rat kidney glutathione synthetase. This enzyme can be used to prepare glutathione analogs, and to raise antibodies against glutathione synthetase. The present invention further relates to a DNA molecule encoding rat kidney glutathione synthetase. The DNA molecule is useful for detecting the presence of the glutathione synthetase gene in animals, and for modifying cell and mammal glutathione production. The DNA molecule can also be used to construct models for evaluation of potential therapies.
- -
-
-
- Compositions and methods of use of mammalian retrotransposons
-
The invention relates to an isolated DNAc molecule comprising a promoter P and an L1 cassette sequence comprising a core L1 retrotransposon element and methods of use thereof.
- -
-
-
- Amino acid conjugates of cyclohexapeptidyl amines
-
Novel amino acid conjugates of cyclohexa-peptidyl amines having the formula STR1 and having antifungal and antiparasital properties are described. The compounds exhibit less acute toxicity than the free amines.
- -
-
-
- Human CRM1 Protein
-
A protein which comprises the sane or substantially the same amino acid sequence as that represented by SEQ ID NO:1, its partial peptide and their salts are disclosed. DNA encoding the protein or its partial peptide is also disclosed. The protein, its partial peptide or a salt thereof is an inhibitory factor of a transcription factor and, therefore, it is useful as medicine such as prophylactic and therapeutic drugs of, for example, tumors. The DNA is useful as a gene diagnosing drug. The antibody against the protein, etc. is also disclosed. The antibody is used for, for example, quantitative determination of the protein, etc. in a specimen fluid. The protein, etc. are also useful as a reagent for screening for compounds or their salts which promote the function of the protein, etc.
- -
-
-
- Hydroxy-kojic acid skin peel
-
The subject of the present invention is a hydroxy-kojic acid skin peel.
- -
-
-
- Regulation of exoprotein in staphylococcus aureus
-
The present invention provides a staphylococcal accessory regulatory protein sar, and the gene encoding that protein(sar). This protein relates to the recognition and control of bacterial infections, particularly infections caused by Staphylococcus aureus (S. aureus). The sar protein and gene are thus useful in preventing or treating staph infections, and in diagnostic kits and assays for detecting the presence of the sar protein and sar gene.
- -
-
-
- T-cell selective interleukin-4 agonists
-
The invention is directed to human IL-4 muteins numbered in accordance with wild-type IL-4 having T cell activating activity, but having reduced endothelial cell activating activity. In particular, the invention is related to human IL-4 muteins wherein the surface-exposed residues of the D helix of the wild-type IL-4 are mutated whereby the resulting mutein causes T cell proliferation, and causes reduced IL-6 secretion from HUVECs, relative to wild-type IL-4. This invention realizes a less toxic IL-4 mutant that allows greater therapeutic use of this interleukin. Further, the invention is directed to IL-4 muteins having single, double and triple mutations represented by the designators R121A, R121D, R121E, R121F, R121H, R1211, R121K, R121N, R121P, R121T, R121W; Y124A, Y124Q, Y124R, Y124S, Y124T; Y124A/S125A, T13D/R121E; and R121T/E122F/Y124Q, when numbered in accordance with wild type IL-4 (His=1). The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.
- -
-
-
- PEPTIDE LIGANDS FOR AFFINITY PURIFICATION OF HUMAN FACTOR VIII
-
Peptides which bind Factor VIII are disclosed. The peptides have available Factor VIII binding domains having a Trp-His-Tyr-Tyr-His-Gly, His-Ile-Gln-His-Tyr-His, or His-Gln-Tyr-Gly-Tyr-His sequence. Peptides having at least one of these Factor VIII binding domains are immobilized upon a chromatographic substrate in a preferred embodiment of the invention. This preferred embodiment is useful in a chromatography process to purify human Factor VIII.
- -
-
-
- Materials and methods for detection and treatment of insulin-dependent diabetes
-
The method and compositions of this invention provide an effective and reliable substitute for the currently employed ICA assay for diabetes. By providing a method for detecting autoantibodies to GAD65, IA-2 and a previously unidentified antigen termed IA-2β herein, the method provides a chemical assay which has improved reliability. In addition, these antigens may be employed in therapeutic regimens aimed at achieving amelioration of the clinical condition.
- -
-
-
- Complexation of the basic amino acids lysine and arginine by three sulfonatocalix[n]arenes (n = 4, 6 and 8) in water: Microcalorimetric determination of the Gibbs energies, enthalpies and entropies of complexation
-
The complexes formed between three p-sulfonatocalix[n]arenes (n = 4, 6 and 8) and the amino acids lysine and arginine in water have been studied by microcalorimetry, at 298.15 K. For each system, both the apparent association constant and enthalpy of reaction have been extracted from the calorimetric data. The Gibbs energies, enthalpies and entropies of complexation have been determined both in acidic medium (pH 1) and in slightly basic medium (pH 8). The thermodynamic parameters for the complexation of arginine markedly differ from those for the complexation of lysine. The three hosts show very different thermodynamic behaviours. Our results are consistent with the formation of 1:1 complexes with the calix[4]arenesulfonate and the calix[6]arenesulfonate and with the formation of 1:1 and 1:2 complexes with the calix[8]arenesulfonate. Whereas the calix[4]arenesulfonate forms relatively strong complexes, the calix[6]arenesulfonate and the calix[8]arenesulfonate form only weak complexes. In all cases, the complexation is driven by a favourable enthalpy change. The enthalpies and entropies of complexing of arginine by the calix[6]arenesulfonate are remarkably negative. The enthalpies and entropies of complexation of the two amino acids by the cyclic tetramer and by the cyclic hexamer become more negative when the pH is changed from 8 to 1; the same effect is observed upon binding of the cyclic octamer with the first guest whereas the opposite effect is observed upon addition of the second guest.
- Douteau-Guevel, Nathalie,Coleman, Anthony W.,Morel, Jean-Pierre,Morel-Desrosiers, Nicole
-
p. 629 - 633
(2007/10/03)
-
- Esters and amides of substituted pyrrole acetic acids
-
Esters and amides of substituted pyrrole acetic acids are useful in the treatment of colonic polyps.
- -
-
-
